Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:BTAINASDAQ:GLYCNASDAQ:NOVN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.54+2.2%$0.56$0.40▼$1.07$11.07M2.2336,345 shs559,626 shsBTAIBioXcel Therapeutics$1.73+5.5%$1.62$1.17▼$25.12$9.93M-0.121.21 million shs96,924 shsGLYCGlycoMimetics$0.16-6.6%$21.40$14.06▼$63.00$10.00M1.6268,818 shs1.05 million shsNOVNNovan$0.00$0.08▼$3.33$2.64M-0.06602,421 shs7.19 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+2.23%-2.00%+3.20%+4.77%-46.58%BTAIBioXcel Therapeutics+5.49%-3.35%+20.14%-26.69%-91.14%GLYCGlycoMimetics0.00%-99.07%-99.40%-99.43%-99.36%NOVNNovan0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.5443 of 5 stars0.04.00.00.00.60.80.6BTAIBioXcel Therapeutics3.6666 of 5 stars3.32.00.04.50.61.70.6GLYCGlycoMimetics1.776 of 5 stars0.03.00.04.63.11.70.0NOVNNovanN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/ABTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,362.43% UpsideGLYCGlycoMimetics 2.50Moderate BuyN/AN/ANOVNNovan 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NOVN, AIMD, BTAI, and GLYC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025GLYCGlycoMimeticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/19/2025BTAIBioXcel TherapeuticsRODMAN&RENSHAWSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/19/2025BTAIBioXcel TherapeuticsRodman & RenshawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$65.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K565.61N/AN/A$1.10 per share0.50BTAIBioXcel Therapeutics$2.27M4.62N/AN/A($30.01) per share-0.06GLYCGlycoMimetics$10K1,000.25N/AN/A$0.08 per share1.94NOVNNovan$24.71M0.00N/AN/A$0.19 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$1.29N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)BTAIBioXcel Therapeutics-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)GLYCGlycoMimetics-$37.88M-$0.46N/AN/AN/AN/A-230.74%-177.39%8/6/2025 (Estimated)NOVNNovan-$31.31M-$1.32N/AN/AN/A-128.61%-700.28%-39.58%N/ALatest NOVN, AIMD, BTAI, and GLYC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GLYCGlycoMimetics-$5.00-$4.00+$1.00-$0.04N/AN/A5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 million3/27/2025Q4 2024BTAIBioXcel Therapeutics-$4.36-$3.57+$0.79-$3.57$0.72 million$0.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ABTAIBioXcel TherapeuticsN/AN/AN/AN/AN/AGLYCGlycoMimeticsN/AN/AN/AN/AN/ANOVNNovanN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.842.001.91BTAIBioXcel TherapeuticsN/A1.481.45GLYCGlycoMimeticsN/A1.921.92NOVNNovanN/A0.740.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ABTAIBioXcel Therapeutics30.68%GLYCGlycoMimetics75.19%NOVNNovan14.51%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%BTAIBioXcel Therapeutics21.20%GLYCGlycoMimetics8.70%NOVNNovan1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4020.76 million18.61 millionNot OptionableBTAIBioXcel Therapeutics906.06 million4.77 millionOptionableGLYCGlycoMimetics5064.53 million58.90 millionOptionableNOVNNovan9028.02 million27.65 millionNot OptionableNOVN, AIMD, BTAI, and GLYC HeadlinesRecent News About These CompaniesHow Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug marketSeptember 18, 2024 | invezz.comNovartis AGFebruary 27, 2024 | wsj.comNovartis AG Registered SharesFebruary 16, 2024 | morningstar.comNovartis AG Registered Shares NOVNOctober 31, 2023 | morningstar.comNovan: Regulation Fd Disclosure, Financial Statements And ExhibitsOctober 25, 2023 | cbonds.comNovan reaches deals to sell assets in bankruptcy caseSeptember 8, 2023 | bizjournals.comFirm Retention Summary: NovanAugust 8, 2023 | msn.comNovan (NOVN) Price Target Increased by 43.52% to 15.81August 3, 2023 | msn.comNovan files patent for a composition and method of treating skinAugust 1, 2023 | pharmaceutical-technology.comInsider Sale Alert: Novan Inc. [NOVN] – Is it Time to sell?July 25, 2023 | knoxdaily.comNOVN short interest surges, indicating growing pessimism among investorsJuly 21, 2023 | knoxdaily.comNOVN stock rated an Overweight by Cantor FitzgeraldJuly 18, 2023 | knoxdaily.comNovan Shares Hit 52-Week Low After Bankruptcy DeclarationJuly 17, 2023 | marketwatch.comDurham biotech Novan to sell assets, files for bankruptcyJuly 17, 2023 | wraltechwire.comPotential Price Increase for Novan Inc. (NOVN) After Recent Insider ActivityJuly 11, 2023 | knoxdaily.comNovan Inc. [NOVN] Investment Guide: What You Need to KnowJuly 3, 2023 | knoxdaily.comCIMB appoints Novan Amirudin as CIMB Investment Bank CEOJune 16, 2023 | malaymail.comCIMB appoints Novan Amirudin as CEO of CIMB Investment BankJune 16, 2023 | thestar.com.myNovan Amirudin new CIMB Investment Bank CEOJune 16, 2023 | freemalaysiatoday.comDurham pharma Novan slashes 50% of workforce, mulls sale of assetsJune 1, 2023 | wraltechwire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNOVN, AIMD, BTAI, and GLYC Company DescriptionsAinos NASDAQ:AIMD$0.54 +0.01 (+2.23%) As of 06/18/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.BioXcel Therapeutics NASDAQ:BTAI$1.73 +0.09 (+5.49%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.76 +0.03 (+1.79%) As of 06/18/2025 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.GlycoMimetics NASDAQ:GLYC$0.16 -0.01 (-6.63%) Closing price 06/13/2025Extended Trading$0.16 0.00 (0.00%) As of 06/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.Novan NASDAQ:NOVNNovan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
